118Tip A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Camrelizumab Plus Chemotherapy with or Without Radiation Therapy (RT) As First-Line Treatment for Patients with Brain Metastatic Non-Small Cell Lung Cancer (BM-NSCLC; CTONG2003): Trial in Progress
J. Yang,Y. Pan,F. Ning,L. Lin,X. Hu,S. Ma,Q. Yu,C. Wang,X. Wang,R. Ma,X. Zhang,G. Lin,J. Zhao,Y. Chen,J. Cui,G. Wu,N. Yang,Y-L. Wu
DOI: https://doi.org/10.1016/j.annonc.2021.10.136
IF: 51.769
2021-01-01
Annals of Oncology
Abstract:BackgroundAt diagnosis, 10%-15% NSCLC patients have brain metastases. BM-NSCLC suffer worse prognosis. For BM-NSCLC, local therapies, e.g., surgery and radiation therapy, are the mainstream of treatment. Immunotherapy combined with or without chemotherapy is first-line standard of care for NSCLC. Immunotherapy showed trends for benefit in BM-NSCLC and a synergistic effect with radiation therapy. However, there is a lack of high-quality evidence on additional immunotherapy on chemotherapy for BM-NSCLC. The present phase III trial aims to confirm camrelizumab, an anti-programmed cell death protein-1 antibody, plus chemotherapy with or without stereotactic or whole brain RT as first-line treatment for BM-NSCLC without driver gene mutation.Trial DesignTreatment-naïve, EGFR/ALK-negative NSCLC aged 18-75 years, with ≥ three brain metastatic lesions or one to two unresectable brain metastatic lesions are eligible. Approximately 200 patients will be randomized (1:1) to receive camrelizumab (200 mg, D1) or placebo plus chemotherapy (D1) for a 21-day cycle. Stereotactic or whole brain RT will be performed at the discretion of investigator, which will be completed within 42 days after first dose of study drugs. Stratification factors include histological type (non-squamous, squamous NSCLC), number of brain metastatic lesions (one to five, ≥ six), and planned radiation therapy (yes, no). The chemotherapy regimens are pemetrexed (500 mg/m2) for non-squamous NSCLC or paclitaxel (175 mg/m2)/albumin-bound paclitaxel (260 mg/m2) for squamous NSCLC plus carboplatin (area under the curve 5)/cisplatin (75 mg/m2). After four to six cycles, camrelizumab or placebo plus pemetrexed, and single-agent camrelizumab or placebo will be administrated as maintenance treatment for non-squamous and squamous NSCLC, respectively. The primary endpoint is intracranial PFS. The secondary endpoints include intracranial ORR, ORR, PFS, OS, duration of response, quality of life, cognitive functioning, and safety. Recruitment began in Apr 2021.Clinical trial identificationNCT04768075.Editorial acknowledgementWe thank the medical writing support from Jiangsu Hengrui Pharmaceuticals Co., Ltd.Legal entity responsible for the studyGuangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences.FundingChinese Thoracic Oncology Group (CTONG).DisclosureAll authors have declared no conflicts of interest. BackgroundAt diagnosis, 10%-15% NSCLC patients have brain metastases. BM-NSCLC suffer worse prognosis. For BM-NSCLC, local therapies, e.g., surgery and radiation therapy, are the mainstream of treatment. Immunotherapy combined with or without chemotherapy is first-line standard of care for NSCLC. Immunotherapy showed trends for benefit in BM-NSCLC and a synergistic effect with radiation therapy. However, there is a lack of high-quality evidence on additional immunotherapy on chemotherapy for BM-NSCLC. The present phase III trial aims to confirm camrelizumab, an anti-programmed cell death protein-1 antibody, plus chemotherapy with or without stereotactic or whole brain RT as first-line treatment for BM-NSCLC without driver gene mutation. At diagnosis, 10%-15% NSCLC patients have brain metastases. BM-NSCLC suffer worse prognosis. For BM-NSCLC, local therapies, e.g., surgery and radiation therapy, are the mainstream of treatment. Immunotherapy combined with or without chemotherapy is first-line standard of care for NSCLC. Immunotherapy showed trends for benefit in BM-NSCLC and a synergistic effect with radiation therapy. However, there is a lack of high-quality evidence on additional immunotherapy on chemotherapy for BM-NSCLC. The present phase III trial aims to confirm camrelizumab, an anti-programmed cell death protein-1 antibody, plus chemotherapy with or without stereotactic or whole brain RT as first-line treatment for BM-NSCLC without driver gene mutation. Trial DesignTreatment-naïve, EGFR/ALK-negative NSCLC aged 18-75 years, with ≥ three brain metastatic lesions or one to two unresectable brain metastatic lesions are eligible. Approximately 200 patients will be randomized (1:1) to receive camrelizumab (200 mg, D1) or placebo plus chemotherapy (D1) for a 21-day cycle. Stereotactic or whole brain RT will be performed at the discretion of investigator, which will be completed within 42 days after first dose of study drugs. Stratification factors include histological type (non-squamous, squamous NSCLC), number of brain metastatic lesions (one to five, ≥ six), and planned radiation therapy (yes, no). The chemotherapy regimens are pemetrexed (500 mg/m2) for non-squamous NSCLC or paclitaxel (175 mg/m2)/albumin-bound paclitaxel (260 mg/m2) for squamous NSCLC plus carboplatin (area under the curve 5)/cisplatin (75 mg/m2). After four to six cycles, camrelizumab or placebo plus pemetrexed, and single-agent camrelizumab or placebo will be administrated as maintenance treatment for non-squamous and squamous NSCLC, respectively. The primary endpoint is intracranial PFS. The secondary endpoints include intracranial ORR, ORR, PFS, OS, duration of response, quality of life, cognitive functioning, and safety. Recruitment began in Apr 2021. Treatment-naïve, EGFR/ALK-negative NSCLC aged 18-75 years, with ≥ three brain metastatic lesions or one to two unresectable brain metastatic lesions are eligible. Approximately 200 patients will be randomized (1:1) to receive camrelizumab (200 mg, D1) or placebo plus chemotherapy (D1) for a 21-day cycle. Stereotactic or whole brain RT will be performed at the discretion of investigator, which will be completed within 42 days after first dose of study drugs. Stratification factors include histological type (non-squamous, squamous NSCLC), number of brain metastatic lesions (one to five, ≥ six), and planned radiation therapy (yes, no). The chemotherapy regimens are pemetrexed (500 mg/m2) for non-squamous NSCLC or paclitaxel (175 mg/m2)/albumin-bound paclitaxel (260 mg/m2) for squamous NSCLC plus carboplatin (area under the curve 5)/cisplatin (75 mg/m2). After four to six cycles, camrelizumab or placebo plus pemetrexed, and single-agent camrelizumab or placebo will be administrated as maintenance treatment for non-squamous and squamous NSCLC, respectively. The primary endpoint is intracranial PFS. The secondary endpoints include intracranial ORR, ORR, PFS, OS, duration of response, quality of life, cognitive functioning, and safety. Recruitment began in Apr 2021. Clinical trial identificationNCT04768075. NCT04768075. Editorial acknowledgementWe thank the medical writing support from Jiangsu Hengrui Pharmaceuticals Co., Ltd. We thank the medical writing support from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Legal entity responsible for the studyGuangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences. Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences. FundingChinese Thoracic Oncology Group (CTONG). Chinese Thoracic Oncology Group (CTONG).